Justin Taylor, M.D., a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller ...

A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a ...

Osaka, Japan - A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus ...

AI is being used to model gene regulation and predict cellular behavior from transcriptomic data. Learn how these tools aid ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

When available, the educational toolkit will provide patients with sickle cell disease information on the gene therapy process, what to expect from therapy, and the importance of follow-up care.

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 /uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

(Reuters) -Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its ...

In this interview, we explore the limitations of pDNA, the advantages of mcDNA and how NunaBio’s technology could unlock new ...

Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular ...